デフォルト表紙
市場調査レポート
商品コード
1629602

ヘモクロマトーシス市場:タイプ別、診断方法別(血液検査、画像技術)、治療タイプ別、年齢層別、エンドユーザー別、地域別

Hemochromatosis Market, By Type, By Diagnosis Method (Blood Tests, Imaging Techniques, By Treatment Type, By Age Group, By End User, By Geography


出版日
ページ情報
英文 140 Pages
納期
2~3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
ヘモクロマトーシス市場:タイプ別、診断方法別(血液検査、画像技術)、治療タイプ別、年齢層別、エンドユーザー別、地域別
出版日: 2024年11月28日
発行: Coherent Market Insights
ページ情報: 英文 140 Pages
納期: 2~3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界のヘモクロマトーシスの市場規模は、2024年に16億米ドルと推定され、2024年から2031年までのCAGRは6%を示し、2031年には24億1,000万米ドルに達すると予測されています。

レポート範囲 レポート詳細
基準年 2023 2024年の市場規模 16億米ドル
実績データ 2019年から2023年まで 予測期間 2024年から2031年まで
予測期間2024年から2031年 CAGR: 6.00% 2031年の価値予測 24億1,000万米ドル
図.ヘモクロマトーシス市場 地域別シェア(%)、2024年
Hemochromatosis Market-IMG1

遺伝性ヘモクロマトーシスの有病率の増加や鉄過剰症に関する意識の高まりなど、いくつかの要因がヘモクロマトーシスの治療と管理に対する需要を促進しています。

市場力学:

世界のヘモクロマトーシス市場の成長は、主に全世界における遺伝性ヘモクロマトーシスの有病率の上昇に牽引されています。Medscapeの推計によると、2023年6月には、約100万人のアメリカ人が遺伝性ヘモクロマトーシスに罹患しており、未診断のままです。鉄過剰症の早期診断と治療に対する意識の高まりは、市場成長にプラスの影響を与えています。さらに、ヘモクロマトーシスの早期発見のためのスクリーニングプログラムの採用が増加していることが、市場の成長をさらに促進しています。しかし、遺伝子検査や肝生検の実施に伴う高額な費用が、ある程度は市場成長の妨げになる可能性があります。とはいえ、先進的な診断法の開発と遺伝子検査の導入のための継続的な研究は、予測期間中、市場企業に有利な機会を創出すると期待されています。

本調査の主な特徴

当レポートでは、世界のヘモクロマトーシス市場を詳細に分析し、2023年を基準年とした予測期間(2024年~2031年)の市場規模(10億米ドル)および複合年間成長率(CAGR%)を掲載しています。

また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。

また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。

企業ハイライト、製品ポートフォリオ、主要なハイライト、財務実績、戦略などのパラメータに基づいて、世界のヘモクロマトーシス市場における主要企業をプロファイルしています。

本調査の対象となる主要企業Novartis AG, Sanofi S.A., Amgen Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Ironwood Pharmaceuticals, Inc., Celgene Corporation, Genentech, Inc., Daiichi Sankyo Company, Limited, Teva Pharmaceutical Industries Ltd., HemoShear Therapeutics, LLC, Erytech Pharma S.A., Alnylam Pharmaceuticals, Inc., HemaCare Corporation, and Invitae Corp.

本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。

この調査レポートは、投資家、サプライヤー、製品メーカー、販売業者、新規参入者、財務アナリストなど、この業界のさまざまな利害関係者を対象としています。

利害関係者は、世界のヘモクロマトーシスの市場分析に使用される様々な戦略マトリックスを通じて、意思決定を容易にすることができます。

目次

第1章 調査の目的と前提条件

  • 調査目的
  • 前提条件
  • 略語

第2章 市場の展望

  • レポートの説明
    • 市場の定義と範囲
  • エグゼクティブサマリー

第3章 市場力学、規制、動向分析

  • 市場力学
  • 影響分析
  • 主な発展
  • 規制シナリオ
  • 製品の発売/承認
  • PEST分析
  • PORTERの分析
  • 合併と買収のシナリオ
  • 業界動向

第4章 世界のヘモクロマトーシス市場、タイプ別、2019年-2031年

  • 原発性ヘモクロマトーシス(遺伝性)
  • 二次性ヘモクロマトーシス(後天性)

第5章 世界のヘモクロマトーシス市場、診断方法別、2019年-2031年

  • 血液検査
  • 血清フェリチン
  • トランスフェリン飽和度
  • イメージング技術
  • 磁気共鳴画像(MRI)
  • コンピュータ断層撮影(CT)スキャン
  • 肝生検
  • 遺伝子検査

第6章 世界のヘモクロマトーシス市場、治療タイプ別、2019年-2031年

  • 瀉血
  • キレート療法
  • 食事管理
  • その他

第7章 世界のヘモクロマトーシス市場、年齢層別、2019年-2031年

  • 小児
  • 成人
  • 高齢者

第8章 世界のヘモクロマトーシス市場、エンドユーザー別、2019年-2031年

  • 病院
  • 診断検査室
  • 外科センター
  • ホームケア設定

第9章 世界のヘモクロマトーシス市場、地域別、2019年-2031年

  • 北米
  • ラテンアメリカ
  • 欧州
  • アジア太平洋
  • 中東
  • アフリカ

第10章 競合情勢

  • Novartis AG
  • Sanofi S.A.
  • Amgen Inc.
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Ironwood Pharmaceuticals, Inc.
  • Celgene Corporation
  • Genentech, Inc.
  • Daiichi Sankyo Company, Limited
  • Teva Pharmaceutical Industries Ltd.
  • HemoShear Therapeutics, LLC
  • Erytech Pharma S.A.
  • Alnylam Pharmaceuticals, Inc.
  • HemaCare Corporation
  • Invitae Corp.

第11章 アナリストの推奨事項

  • 運命の輪
  • アナリストの見解
  • 一貫した機会マップ

第12章 参考文献と調査手法

  • 参考文献
  • 調査手法
  • 出版社について
目次
Product Code: CMI7544

The global hemochromatosis market is estimated to be valued at USD 1.60 Bn in 2024 and is expected to reach USD 2.41 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2024: US$ 1.60 Bn
Historical Data for: 2019 To 2023 Forecast Period: 2024 To 2031
Forecast Period 2024 to 2031 CAGR: 6.00% 2031 Value Projection: US$ 2.41 Bn
Figure. Hemochromatosis Market Share (%), By Region 2024
Hemochromatosis Market - IMG1

Several factors such as increasing prevalence of hereditary hemochromatosis and rising awareness regarding iron overload disorders are driving the demand for hemochromatosis treatment and management.

Market Dynamics:

The global hemochromatosis market growth is primarily driven by the rising prevalence of hereditary hemochromatosis across the globe. As per estimates from Medscape, in June 2023, around 1 million Americans suffer from hereditary hemochromatosis which remains undiagnosed. Increasing awareness about the early diagnosis and treatment of iron overload disorders is positively impacting the market growth. Moreover, increasing adoption of screening programs for the early detection of hemochromatosis is further fueling the market growth. However, high costs associated with genetic testing and liver biopsy procedures may hinder the market growth to some extent. Nevertheless, ongoing research for the development of advanced diagnostics and introduction of genetic testing are expected to create lucrative opportunities for market players over the forecast period.

Key Features of the Study:

This report provides in-depth analysis of the global hemochromatosis market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global hemochromatosis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study Novartis AG, Sanofi S.A., Amgen Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Ironwood Pharmaceuticals, Inc., Celgene Corporation, Genentech, Inc., Daiichi Sankyo Company, Limited, Teva Pharmaceutical Industries Ltd., HemoShear Therapeutics, LLC, Erytech Pharma S.A., Alnylam Pharmaceuticals, Inc., HemaCare Corporation, and Invitae Corp.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global hemochromatosis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hemochromatosis market.

Market Segmentation

  • By Type Insights (Revenue, USD Bn, 2019 - 2031)
    • Primary Hemochromatosis (Hereditary)
    • Secondary Hemochromatosis (Acquired)
  • By Diagnosis Method Insights (Revenue, USD Bn, 2019 - 2031)
    • Blood Tests
    • Serum Ferritin
    • Transferrin Saturation
    • Imaging Techniques
    • Magnetic Resonance Imaging (MRI)
    • Computed Tomography (CT) scans
    • Liver Biopsy
    • Genetic Testing
  • By Treatment Type Insights (Revenue, USD Bn, 2019 - 2031)
    • Phlebotomy
    • Chelation Therapy
    • Dietary Management
    • Others
  • By Age Group Insights (Revenue, USD Bn, 2019 - 2031)
    • Pediatric
    • Adult
    • Geriatric
  • By End User Insights (Revenue, USD Bn, 2019 - 2031)
    • Hospitals
    • Diagnostic Laboratories
    • Surgical Centers
    • Home Care Settings
  • Regional Insights (Revenue, USD Bn, 2019 - 2031)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Novartis AG
    • Sanofi S.A.
    • Amgen Inc.
    • Takeda Pharmaceutical Company Limited
    • Pfizer Inc.
    • Ironwood Pharmaceuticals, Inc.
    • Celgene Corporation
    • Genentech, Inc.
    • Daiichi Sankyo Company, Limited
    • Teva Pharmaceutical Industries Ltd.
    • HemoShear Therapeutics, LLC
    • Erytech Pharma S.A.
    • Alnylam Pharmaceuticals, Inc.
    • HemaCare Corporation
    • Invitae Corp.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Hemochromatosis Market, By Type
    • Global Hemochromatosis Market, By Diagnosis Method
    • Global Hemochromatosis Market, By Treatment Type
    • Global Hemochromatosis Market, By Age Group
    • Global Hemochromatosis Market, By End User
    • Global Hemochromatosis Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Driver
    • Restraint
    • Opportunity
  • Impact Analysis
  • Key Developments
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Industry Trends

4. Global Hemochromatosis Market, By Type, 2019-2031, (USD Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Primary Hemochromatosis (Hereditary)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Secondary Hemochromatosis (Acquired)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Global Hemochromatosis Market, By Diagnosis Method, 2019-2031, (USD Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Blood Tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Serum Ferritin
  • Transferrin Saturation
  • Imaging Techniques
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Magnetic Resonance Imaging (MRI)
  • Computed Tomography (CT) scans
  • Liver Biopsy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Genetic Testing
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Hemochromatosis Market, By Treatment Type, 2019-2031, (USD Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Phlebotomy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Chelation Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Dietary Management
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Hemochromatosis Market, By Age Group, 2019-2031, (USD Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Pediatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Adult
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Geriatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Hemochromatosis Market, By End User, 2019-2031, (USD Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Diagnostic Laboratories
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Surgical Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Home Care Settings
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

9. Global Hemochromatosis Market, By Region, 2019 - 2031, Value (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2024, 2027 & 2031, Value (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2020 - 2031, Value (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Diagnosis Method, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Diagnosis Method, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Diagnosis Method, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Diagnosis Method, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Diagnosis Method, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Diagnosis Method, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Country/Region, 2019 - 2031, Value (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

10. Competitive Landscape

  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sanofi S.A.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Amgen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Takeda Pharmaceutical Company Limited
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer Inc.
  • Ironwood Pharmaceuticals, Inc.
  • Celgene Corporation
  • Genentech, Inc.
  • Daiichi Sankyo Company, Limited
  • Teva Pharmaceutical Industries Ltd.
  • HemoShear Therapeutics, LLC
  • Erytech Pharma S.A.
  • Alnylam Pharmaceuticals, Inc.
  • HemaCare Corporation
  • Invitae Corp.

11. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

12. References and Research Methodology

  • References
  • Research Methodology
  • About us